TScan Therapeutics, Inc. Common Stock

TCRXNASDAQ • USD
ThemeHealthcare - Oncology›Cell & Gene Therapy for Cancer
0.91 USD
↗ 0.02 (1.80%)AT CLOSE (11:59 AM EDT)
0.92
↗ 0.00 (0.35%)
POST MARKET (AS OF 07:02 PM EDT)
Post Market
AS OF 07:02 PM EDT
0.92
↗ 0.00 (0.35%)
🔴Market: CLOSED

Shares of TScan Therapeutics, Inc. Common Stock (TCRX) are trading at $0.91. The stock presents a bearish profile across the board: technical indicators signal "Strong Sell" and our fundamental models agree with a "Sell" rating. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics suggest TCRX is trading at a discount to its peers, earning an "Attractively Valued" rating.

Technical & fundamental data as of Jul 17, 2026.

Open?$0.89
High?$0.93
Low?$0.88
Prev. Close?$0.90
Volume?144.0K
Avg. Volume?795.0K
VWAP?$0.91
Rel. Volume?0.18x
Bid / Ask
Bid?$0.79 × 100
Ask?$1.06 × 100
Spread?$0.27
Midpoint?$0.92
Valuation & Ratios
Market Cap?58.8M
Shares Out?61.1M
Float?50.6M
Float %?82.9%
P/E Ratio?N/A
P/B Ratio?0.61
EPS?-$1.90
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Themes
Healthcare - Oncology›Cell & Gene Therapy for CancerHealthcare - Genomics & Precision Medicine›Gene Therapy & Gene Editing
Employees
142
Market Cap
58.7M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.tscan.com
Listed
2021-07-16
Address
830 WINTER STREET
WALTHAM, MA 02451
Phone: 857-399-9500
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
12
Z-Score?
0
Momentum?
50
Short Sent.?
75
Piotroski F-Score?2/9Weak
Altman Z-Score?-4.75Distress
Confidence?48%Low
Full Fundamental Analysis →
Short InterestLow
Short % of Float?1.40%Low
Short Interest?708.2K
Days to Cover?1.0
Free Float50.6M
Avg Daily Volume782.9K
Settlement Date2026-06-30
Financial Health
Current Ratio?6.65Strong
Quick Ratio?6.65Strong
Cash Ratio?6.41Strong
Debt/Equity?0.34Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
92/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
0.61CHEAP▾
P/S?
Peers
100
S&P
19
6.44FAIR▾
P/FCF?
N/A▾
EV/EBITDA?
Peers
100
S&P
97
0.3CHEAP▾
EV/Sales?
S&P
97
-4.00CHEAP▾
Returns & Efficiency
ROE?
S&P
3
-128.3%WEAK▾
ROA?
S&P
3
-61.5%WEAK▾
Cash Flow & Enterprise
FCF?$-124957000
Enterprise Value?$-36587265
Fundamentals ratios updated end of day
MarketsMoversWatchlist